Novo Nordisk stock was dropping on Wednesday after Roche said it had licensed a promising obesity drug in a deal that could ...

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

March 5 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said ... The Danish drugmaker will also offer home delivery for the drug, which can cost patients more than $1,000 a month if they ...

Novo Nordisk will offer its weight loss drug Wegovy for less than half of its usual price per month through a new direct-to-consumer online pharmacy. The cash-pay offering is available to millions ...

Novo Nordisk is introducing a direct-to-patient ... still follow a strict set of regulations and standards. Compounders offer their versions of semaglutide at a cheaper price than Wegovy and ...

The CEO of <strong>Novo Nordisk</strong> warned of the impact of tariffs on the pharmaceutical industry. Weight-loss drugs, including Ozempic and Wegovy, could cost ...

Novo Nordisk A/S is following in rival Eli Lilly ... drug at a reduced cost of $499 a month to cash-paying patients. The offer is for uninsured patients or those with commercial insurance ...